Analytical Data
-
基因名
CDK2-CCNE1
- Application
-
别名
CDKN2; p33(CDK2); Cell division protein kinase 2; p33 protein kinase
-
种属
Mouse
-
表达系统
E. coli
-
标签
Two N- s, His- & MBP-
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
P97377
-
表达区间
Ala93~His211
-
分子量
63kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Cyclin-dependent kinase 2 (CDK2) and cyclin E1 (CCNE1) play critical roles in cell cycle regulation, particularly in the transition from the G1 phase to the S phase. Dysregulation of the CDK2-CCNE1 complex has been implicated in various types of cancer, as it can lead to uncontrolled cell proliferation. Researchers have focused on characterizing the CDK2-CCNE1 recombinant protein to better understand its structural properties, functional mechanisms, and interactions with other cell cycle regulators. The study of this protein complex not only enhances our understanding of the cell cycle but also opens avenues for the development of targeted therapies that could inhibit its activity in cancerous cells. By employing techniques such as X-ray crystallography and biochemical assays, researchers aim to elucidate the molecular basis of CDK2-CCNE1 activity, identify potential inhibitors, and assess the role of post-translational modifications in its function. These insights are essential for designing novel anticancer strategies that could selectively disrupt the aberrations associated with CDK2 and CCNE1, ultimately contributing to more effective cancer treatments.
